Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
213.20
+1.31 (+0.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
39
40
Next >
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry?
August 09, 2022
According to Grand View Research, the global cell therapy market was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% between 2021 and 2028.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
August 05, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
7 Cheap Blue-Chip Stocks to Buy Before They Rebound
August 05, 2022
The bear market has hit even top firms. That means investors should consider these cheap blue-chip stocks to buy now.
Via
InvestorPlace
How Is The Market Feeling About Biogen?
August 01, 2022
Biogen's (NASDAQ:BIIB) short percent of float has fallen 17.34% since its last report. The company recently reported that it has 2.09 million shares sold short, which is 1.43% of...
Via
Benzinga
Bill Gates, Jeff Bezos Unite To 'Change The Course' Of Neurological Disorder Impacting 6.5 Million Americans
July 30, 2022
It’s a well-known fact that Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates, through his Bill & Melinda Gates Foundation, is working toward eliminating infectious diseases and eradicating...
Via
Benzinga
Biogen (BIIB) Stock Dips Following Q2 Earnings Report
July 20, 2022
Biogen delivered a Q2 beat on the top and bottom lines, but a lack of important disclosures is hurting sentiment for BIIB stock.
Via
InvestorPlace
Earnings Beat, Increased FY22 Outlook, Rising Biosimilar Competition: Biogen's Q2 Highlights
July 20, 2022
Via
Benzinga
Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today
July 28, 2022
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 2.68% on an annualized basis producing an average annual return of 9.81%. Currently, Biogen has a market capitalization of...
Via
Benzinga
A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea
July 28, 2022
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, received an AU$1 million (US$694,000) gran
Via
Benzinga
7 Undervalued S&P 500 Stocks to Buy Before Wall Street Catches On
July 27, 2022
July's heat on Wall Street could start to sizzle in August with these undervalued S&P 500 stocks that are ready to buy.
Via
InvestorPlace
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
July 26, 2022
Via
Benzinga
FDA Accepts Biogen's Submission For Neurodegenerative Disease Drug Under Priority Review
July 26, 2022
The U.S. Food and Drug Administration (FDA) has accepted Biogen’s (NASDAQ: BIIB) New Drug Application (NDA) for its lead asset Tofersen for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis...
Via
Benzinga
Recap: Biogen Q2 Earnings
July 20, 2022
Biogen (NASDAQ:BIIB) reported its Q2 earnings results on Wednesday, July 20, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Biogen Stock Falls Despite Beat-And-Raise Q2 Report
July 20, 2022
Biogen stock fell early Wednesday after the biotech company reported adjusted profit of $5.25 per share on sales $2.59 billion in Q2.
Via
Investor's Business Daily
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
July 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
As Snap Spooks Market, Here Are The Hits & Misses Of Q2 Reporting Season
July 23, 2022
Snap, Inc. (NYSE: SNAP) was among the high-profile disappointment thus far in the second-quarter reporting season.
Via
Benzinga
Biogen Whale Trades Spotted
July 22, 2022
Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available...
Via
Benzinga
With All Eyes On Lecanemab Read Out In Alzheimer's, Uncertainty Overshadows Biogen's Q2 Beat
July 21, 2022
Via
Benzinga
Benzinga Before The Bell: Baidu Beats Tesla, Finland Sells $47.5M Bitcoins, Tesla's Bitcoin Sale And Other Top Financial Stories Thursday, July 21
July 21, 2022
CNBC
Via
Benzinga
Tesla to $1,175? Here Are 5 Other Price Target Changes for Thursday
July 21, 2022
Mizuho raised Tesla, Inc. (NASDAQ: TSLA) price target from $1,150 to $1,175. However, Mizuho analyst Vijay Rakesh maintained a Buy rating on the stock. Tesla shares rose 3.3% to $766.88 in pre-market...
Via
Benzinga
Biogen Reveals $900M Settlement In Whistleblower's MS Drug Kickbacks Lawsuit Days Before Trial
July 21, 2022
Biogen, Inc. (NASDAQ: BIIB) disclosed in its second-quarter earnings report that it recorded $900 million related to a settlemen
Via
Benzinga
Stranger Things Do Happen As Netflix Surprises Investors
July 20, 2022
(Wednesday Market Open) The European Commission (EU) has asked its 27 member nations to reduce their natural gas consumption by 15% between August and March 2023. The announcement turned U.S. equity...
Via
Benzinga
Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday
July 21, 2022
Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022.
Via
Benzinga
The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study
July 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Biogen Inc. Q2 Earnings And Revenues Surpass Estimates
July 20, 2022
Biogen Inc. came out with quarterly earnings of $5.25 per share.
Via
Talk Markets
These Biotechs Are Reportedly Reinvigorating Alzheimer's Disease Research With Novel Drugs That Push Beyond Traditional Approaches
July 20, 2022
More than 55 million people worldwide have dementia — with about 60% to 70% of those cases resulting from Alzheimer’s disease — and that number is expected to triple by 2050.
Via
Benzinga
Investors Turn Their Attention To The Earning Season
July 20, 2022
US stock indices rose on Tuesday as investors temporarily put aside recession fears and dived into the reporting season.
Via
Talk Markets
Netflix Earnings NFLX In Motion - What Levels are in Play and also for Tesla TSLA Tomorrow?
July 19, 2022
Netflix reported earnings right after the bell Tuesday and shares surged right on the announcement - but will they hold going into Wednesday morning?
Via
Talk Markets
Apple Upstages Goldman Sachs On Monday, Bringing Rally To A Screeching Halt
July 19, 2022
(Tuesday Market Open) A big slide in the U.S. dollar appears to be pushing stocks higher Tuesday as a slew of earnings arrived before the opening bell.
Via
Benzinga
Earnings Scheduled For July 20, 2022
July 20, 2022
Companies Reporting Before The Bell • Wipro (NYSE:WIT) is projected to report quarterly earnings at $0.08 per share on revenue of $2.80 billion.
Via
Benzinga
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.